The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.
 
MarnixMarnix Heimen Geukes Foppen
No Relationships to Disclose
 
Marco Donia
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Troels Holz Borch
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Özcan Met
No Relationships to Disclose
 
Christian U. Blank
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Roche/Genentech
 
Loes Pronk
No Relationships to Disclose
 
Johannes V. Van Thienen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Inge Marie Svane
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)